Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC98 in advanced malignant solid tumors
NCT04190823Phase 1Active, not recruiting
- Sponsor
- RemeGen
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rc98 in solid tumor, sponsored by RemeGen. Primary endpoints: Adverse events and Maximum Tolerated Dose at 12 months. Started Mar 2020; status: active, not recruiting.
02
Drugs
rc98
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04190823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190823.